Abstract

5 Conservative treatment for PAD - Risk factor management.

Highlights

  • It is recommended that systolic blood pressure should be targeted to 120–129 mm Hg, if tolerated, in most hypertensive patients aged below 65 years, with or without cardiovascular disease

  • It is recommended that systolic blood pressure should be targeted to 130–139 mm Hg, if tolerated, in older (65 years and above) hypertensive patients, with or without cardiovascular disease

  • Patients with diabetes with asymptomatic PAD given 100 mg daily of ASA, have shown neither reduced rates of cardiovascular events nor reduced rates of major amputations compared to placebo-treated patients [17, 200, 201]

Read more

Summary

Conservative treatment for PAD – Risk factor management

Ulrich Franka (Switzerland), Sigrid Nikola (Germany), and Jill Belcha (UK) for the European Society of Vascular Medicine. ESVM Board Authors Vinko Boc* (Slovenia), Marianne Brodmann (Austria), Patrick H Carpentier (France), Ali Chraim* (Ukraine), Caitriona Canning (Ireland); Evangelos Dimakakos* (Greece), Anders Gottsäter (Sweden), Christian Heiss (Germany), Lucia Mazzolai (Switzerland), Juraj Madaric* (Slovakia), Dan Mircea Olinic* (Romania), Zsolt Pécsvárady* (Hungary), Pavel Poredoš* (Slovenia), Isabelle Quéré (France), Karel Roztocil (ESVM President, Czech Republic), Agata Stanek (Poland), Dragan Vasic* (Serbia), Adriana Visonà (Italy), and Jean-Claude Wautrecht* (Belgium). ESVM Country Society Authors Miroslav Bulvas (Czech Republic), Mary-Paula Colgan (Ireland), Walter Dorigo (Italy), Graeme Houston (UK), Thomas Kahan (Sweden), Holger Lawall (Germany), Isak Lindstedt (Sweden), Guillaume Mahe (France), Romeo Martini (Italy), Giles Pernod (France), Stanislaw Przywara (Poland). Marc Righini (Switzerland), Oliver Schlager (Austria), and Piotr Terlecki (Poland)

Objectives of conservative PAD treatment
Cardiovascular risk management in PAD
Smoking
Depression
Dyslipidemia
Diabetes mellitus
Hypertension
Platelet aggregation inhibitors in symptomatic PAD
I I IIb
Platelet aggregation inhibitors in asymptomatic PAD
Findings
Anticoagulants
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call